Alcon (ALC) Stock Price & Analysis
ALC Stock Chart & Stats
- Day’s Range
- $71.27 - $72.72
- 52-Week Range
- $61.84 - $87.64
- Previous Close
- $71.13
- Volume
- 1.36M
- Average Volume (3M)
- 1.65M
- Market Cap
- $35.85B
- Enterprise Value
- $29.78B
- Total Cash (Recent Filing)
- $1.46B
- Total Debt (Recent Filing)
- $5.31B
- Price to Earnings (P/E)
- 55.0
- Beta
- 0.68
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- 0.87
- Last Dividend Ex-Date
- May 06, 2026
- Dividend Yield
- 0.50%
Bulls Say, Bears Say
Bulls Say
Durable Revenue Growth
Multi-year revenue expansion indicates durable demand across Alcon’s eye-care portfolio rather than reliance on a single product or period. Continued growth across franchises and geographies can support operating scale, strengthen customer relationships, and provide a foundation for sustained earnings development.
Broad Product Momentum And Market Position
Market-share gains in contact lenses and rapid adoption of newer products show that Alcon is converting innovation into commercial traction. A broad portfolio spanning surgical, contact-lens, and ocular-health categories can reinforce its competitive position and support recurring customer demand.
Strong Cash Generation And Conservative Leverage
Improving free cash flow and conservative leverage give Alcon financial flexibility to fund product development, commercialization, and shareholder returns without relying heavily on additional borrowing. This supports resilience through investment cycles while preserving capacity for strategic capital allocation.
Bears Say
Recent Profitability And Return Compression
The recent decline in net margin and ROE shows that revenue growth has not fully translated into stronger returns. If operating costs or pricing pressure persist, profitability may remain below prior levels, limiting earnings conversion and reducing the benefit of otherwise healthy gross margins.
PowerVision Program Discontinuation
Ending the PowerVision programs removes a potential long-term accommodating-IOL growth pathway and represents an R&D setback. It may also redirect development resources and leave Alcon with fewer future product options in an area where differentiated innovation could have strengthened its surgical portfolio.
Competitive And Adoption Pressure In Surgical Products
Slower implantables growth and limited Hydrus adoption indicate that competitive launches, reimbursement changes, and customer uptake are constraining parts of Surgical. Persistent pressure in these categories could weaken portfolio growth and make future expansion more dependent on newer launches.
Alcon News
ALC FAQ
What was Alcon’s price range in the past 12 months?
What is Alcon’s market cap?
When is Alcon’s upcoming earnings report date?
How were Alcon’s earnings last quarter?
Is Alcon overvalued?
Does Alcon pay dividends?
What is Alcon’s EPS estimate?
How many shares outstanding does Alcon have?
What happened to Alcon’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Alcon?
What is the TipRanks Smart Score and how is it calculated?
Alcon Stock Smart Score
Company Description
Alcon
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- David J. Endicott
- Employees
- 25,000
- Website
- www.alcon.com
- Address
- Chemin de Blandonnet 8, Geneva, GE, 1214, CH
Alcon (ALC) Earnings & Revenues
ALC Company Deck
ALC Earnings Call
Earnings Call SentimentPositive
The call conveyed a clearly positive operational and financial quarter: 7% consolidated sales growth, strong equipment performance (UNITY), margin expansion (+250 bps gross margin, +160 bps operating margin), EPS and cash-flow strength, and multiple successful new-product introductions (PanOptix Pro, TRYPTYR, Valeda). Notable negatives included the discontinuation of the PowerVision accommodating IOL program, slower growth in implantables and certain glaucoma products, a few one-time margin items and manufacturability timing for UNITY DX. On balance, the positives — consistent revenue and margin expansion, robust cash generation and multiple high-potential product rollouts and market-share gains — outweigh the setbacks.
View all ALC earnings summariesALC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 3 | 7 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 10 | 0 | 2 |











